$ cat ./records/co-founded-the-path-malaria-vaccine-initiative-partnership-with-g-2001.txt
Co-founded the PATH Malaria Vaccine Initiative partnership with GSK to develop RTS,S
[RECORD.TXT] · cat --full
The Gates Foundation, through a grant to the PATH Malaria Vaccine Initiative (MVI), entered a landmark public-private partnership with GlaxoSmithKline Biologicals to fund and develop the RTS,S malaria vaccine — the first vaccine candidate ever to reach advanced clinical trials against a parasitic disease. Over the following 13 years, the MVI invested more than $200 million in the project. The collaboration represented a new model for global health: private philanthropy absorbing the commercial risk that pharmaceutical companies could not justify for a disease affecting primarily the world's poorest populations.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Granted $1 million to IRC, Mercy Corps, and Save the Children for Afghan refugee relief
Next →
Gates Foundation surpasses $500 million in annual disbursements for the second consecutive year
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.